禾元生物-U
(688765)
| 流通市值：31.55亿 | | | 总市值：275.28亿 |
| 流通股本：4097.88万 | | | 总股本：3.58亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 74,818,283.62 | 132,369,158.98 | - | 160,402,334.66 |
| 应收票据及应收账款 | 383,435.88 | 6,359,472.06 | - | 144,362 |
| 应收账款 | 383,435.88 | 6,359,472.06 | - | 144,362 |
| 预付款项 | 9,520,040.82 | 5,038,501.42 | - | 5,039,473.64 |
| 其他应收款合计 | 986,592.58 | 978,559.55 | - | 349,054.91 |
| 存货 | 105,947,637.89 | 80,629,178.22 | - | 50,018,931.96 |
| 其他流动资产 | 49,316,950.12 | 36,200,418.59 | - | 21,388,303.35 |
| 流动资产平衡项目 | 0 | 0 | - | 0 |
| 流动资产合计 | 240,972,940.91 | 261,575,288.82 | - | 237,342,460.52 |
| 非流动资产: | | | | |
| 固定资产 | 573,271,375.63 | 572,143,470.48 | - | 574,495,439.15 |
| 在建工程 | 364,730,685.39 | 245,219,781.91 | - | 133,754,960.52 |
| 使用权资产 | 23,174,992.08 | 23,839,755.53 | - | 25,169,282.43 |
| 无形资产 | 85,069,412.96 | 85,720,129.01 | - | 87,392,440.95 |
| 长期待摊费用 | 3,296,887.07 | 3,198,367.07 | - | 3,558,148.35 |
| 其他非流动资产 | 173,512,482.14 | 125,563,614.03 | - | 99,144.04 |
| 非流动资产平衡项目 | 0 | 0 | - | 0 |
| 非流动资产合计 | 1,223,055,835.27 | 1,055,685,118.03 | - | 824,469,415.44 |
| 资产平衡项目 | 0 | 0 | - | 0 |
| 资产总计 | 1,464,028,776.18 | 1,317,260,406.85 | 1,214,016,300 | 1,061,811,875.96 |
| 流动负债: | | | | |
| 短期借款 | - | 15,010,500 | - | 10,007,777.78 |
| 应付票据及应付账款 | 312,184,284.12 | 199,266,076.53 | - | 175,904,216.94 |
| 应付账款 | 312,184,284.12 | 199,266,076.53 | - | 175,904,216.94 |
| 合同负债 | 3,429,322.51 | 2,400,144.25 | - | 2,449,142.88 |
| 应付职工薪酬 | 4,632,189.55 | 4,094,333.39 | - | 8,464,726.23 |
| 应交税费 | 1,155,126.38 | 881,319.92 | - | 596,544.12 |
| 其他应付款合计 | 6,069,188.92 | 23,042,944.52 | - | 25,400,112.22 |
| 一年内到期的非流动负债 | 48,415,909.72 | 28,015,980.71 | - | 9,632,389.86 |
| 其他流动负债 | 247,275.65 | 82,150.79 | - | 212,094.18 |
| 流动负债平衡项目 | 0 | 0 | - | 0 |
| 流动负债合计 | 376,133,296.85 | 272,793,450.11 | - | 232,667,004.21 |
| 非流动负债: | | | | |
| 长期借款 | 538,601,070.02 | 470,793,933.41 | - | 183,995,895.56 |
| 租赁负债 | 19,652,979.58 | 19,469,344.45 | - | 19,293,248.28 |
| 预计负债 | 1,485,066.89 | 1,485,066.89 | - | 1,485,066.89 |
| 递延收益 | 31,205,960.14 | 21,811,475.48 | - | 23,022,993.12 |
| 非流动负债平衡项目 | 0 | 0 | - | 0 |
| 非流动负债合计 | 590,945,076.63 | 513,559,820.23 | - | 227,797,203.85 |
| 负债平衡项目 | 0 | 0 | - | 0 |
| 负债合计 | 967,078,373.48 | 786,353,270.34 | 655,301,000 | 460,464,208.06 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 268,048,646 | 268,048,646 | - | 268,048,646 |
| 资本公积 | 1,201,533,554.45 | 1,195,847,199.92 | - | 1,184,659,915.47 |
| 未分配利润 | -972,631,797.75 | -932,988,709.41 | - | -851,360,893.57 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | - | 0 |
| 归属于母公司股东权益合计 | 496,950,402.7 | 530,907,136.51 | 558,715,200 | 601,347,667.9 |
| 股东权益平衡项目 | 0 | 0 | - | 0 |
| 股东权益合计 | 496,950,402.7 | 530,907,136.51 | - | 601,347,667.9 |
| 负债和股东权益合计 | 1,464,028,776.18 | 1,317,260,406.85 | - | 1,061,811,875.96 |
| 公告日期 | 2025-10-24 | 2025-09-23 | 2025-06-24 | 2025-03-31 |
| 审计意见(境内) | | 标准无保留意见 | | 标准无保留意见 |